NSC745885

SKU: orb1706899

Description

NSC745885 is a small molecule that selectively induces proteasomal degradation of EZH2, demonstrating potent anti-tumor activity in vitro against various cancer cell lines, including bladder and oral squamous cell carcinoma, while sparing normal cells. Its mechanism supports research in oncology, particularly for studying epigenetic-targeted therapies in preclinical models.

Research Area

Cell Biology, Epigenetics & Chromatin

Key Properties

• CAS Number: 4219-52-7
• MW: 266.27
• Formula: C₁₄H₆N₂O₂S
• SMILES: O=C1c2ccccc2C(=O)c2c1ccc1nsnc21
• Target: Apoptosis,Histone Methyltransferase

Bioactivity

• In Vivo:
  NSC745885 (intraperitoneal injection; 2 mg/kg; once daily; 10 days) significantly reduces tumor size compared to the vehicle control and demonstrates higher safety than doxorubicin.
• In Vitro:
  NSC745885 (0.5-4 μM; 24 hours) enhances annexin V positive cells and reduces XIAP protein levels (0.5-2 μM; 24 or 48 hours) in a dose-dependent manner, significantly decreasing the densities of cultured SAS cells compared to untreated cells, with an IC50 of 0.85 μM after 72 hours’ treatment .

Storage & Handling

• Storage: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

EZH2, NSC 745885, NSC745885, NSC-745885

Compound Identifiers

PubChem CID

3835463